DDInter1595 DDInter1694
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration. The treatment effect was maintained for up to 12 months.
Rilpivirine {u} (Compound) resembles {v} (Compound) Etravirine
Rilpivirine {u} (Compound) binds {v} (Gene) CYP3A4
Rilpivirine {u} (Compound) is included by {v} (Pharmacologic Class) Non-Nucleoside Reverse Transcriptase Inhibitors
Rilpivirine {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Rilpivirine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zafirlukast
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Rilpivirine {u} may lead to a major life threatening interaction when taken with {v} Lumacaftor
Rilpivirine {u} may lead to a major life threatening interaction when taken with {v} Ranitidine
Rilpivirine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Rilpivirine (Compound) resembles Etravirine (Compound)
Rilpivirine (Compound) binds CYP3A4 (Gene)
Rilpivirine (Compound) is included by Non-Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class)
Rilpivirine (Compound) causes Blood creatinine increased (Side Effect)
Rilpivirine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Rilpivirine may lead to a major life threatening interaction when taken with Lumacaftor
Rilpivirine may lead to a major life threatening interaction when taken with Ranitidine
Rilpivirine (Compound) resembles Pazopanib (Compound) and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib